Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody
At the two-year mark, Roche’s Evrysdi (risdiplam) either maintained or improved motor function from a one-year check-up in patients aged 2 to 25 with Types …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
